Chiesi Farmaceutici SpA - Strategic SWOT Analysis Review

October 2020 | 32 pages | ID: C83F3301F2CEN
GlobalData

Abstracts

Chiesi Farmaceutici SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities at its R&D center in Parma and at laboratories in Paris, Chippenham (the UK), Cary (the US) and Lidingo (Sweden. Chiesi is headquartered in Parma, Italy.

Chiesi Farmaceutici SpA Key Recent Developments

Apr 08,2020: Chiesi Group increases support measures and announces new funds for employees, patients and, healthcare providers in response to COVID-19 pandemic
Feb 07,2020: Chiesi forms new rare diseases business unit
Aug 05,2019: Santhera licences Leber’s hereditary optic neuropathy drug to Chiesi
Jul 09,2019: Chiesi Group confirms positive trend to date for 2019
Jun 06,2019: Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Chiesi Farmaceutici SpA - Key Facts
Chiesi Farmaceutici SpA - Key Employees
Chiesi Farmaceutici SpA - Major Products and Services
Chiesi Farmaceutici SpA - History
Chiesi Farmaceutici SpA - Company Statement
Chiesi Farmaceutici SpA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Chiesi Farmaceutici SpA - Business Description
Chiesi Farmaceutici SpA - SWOT Analysis
SWOT Analysis - Overview
Chiesi Farmaceutici SpA - Strengths
Chiesi Farmaceutici SpA - Weaknesses
Chiesi Farmaceutici SpA - Opportunities
Chiesi Farmaceutici SpA - Threats
Chiesi Farmaceutici SpA - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Chiesi Farmaceutici SpA, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Apr 08, 2020: Chiesi Group increases support measures and announces new funds for employees, patients and, healthcare providers in response to COVID-19 pandemic
Feb 07, 2020: Chiesi forms new rare diseases business unit
Aug 05, 2019: Santhera licences Leber’s hereditary optic neuropathy drug to Chiesi
Jul 09, 2019: Chiesi Group confirms positive trend to date for 2019
Jun 06, 2019: Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Chiesi Farmaceutici SpA, Key Facts
Chiesi Farmaceutici SpA, Key Employees
Chiesi Farmaceutici SpA, Major Products and Services
Chiesi Farmaceutici SpA, History
Chiesi Farmaceutici SpA, Subsidiaries
Chiesi Farmaceutici SpA, Joint Venture
Chiesi Farmaceutici SpA, Key Competitors
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Chiesi Farmaceutici SpA, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020